Two cDNA clones encoding the 52-kD form of a protein present in human Ro/SSA ribonucleoprotein complexes were cloned from a X gtl1 human thymocyte cDNA library. These clones reacted with lupus patient sera which had anti-52-kD Ro/SSA antibodies, and with affinity-purified anti-52-kD Ro/ SSA antibodies. Moreover, affinity-purified antibodies isolated from isopropyl-l-D-thiogalactopyranoside-induced proteins of these clones reacted only with the 52-kD protein of lymphocytes in Western blots and precipitated Ro/SSA hY RNAs, confirming that the clones encode a 52-kD Ro/SSA antigen.
Introduction
Ro/SSA is a ribonucleoprotein particle composed of a single polypeptide and one of four small RNA molecules (1) (2) (3) . It is present in all mammalian cells studied but has no known function. The antigenic portions of the Ro/SSA particle reside on the polypeptide chain (4) . Autoantibodies to Ro/SSA are found in the sera of30-50% ofpatients with systemic lupus erythematosus (SLE)' and in at least 50% of patients with primary Sjogren's syndrome (3, 5) . These autoantibodies occur in a higher percentage in patients with subacute cutaneous lupus erythematosus, and in essentially all neonatal lupus erythematosus patients with congenital heart block (6, 7) . The presence of anti-Ro/SSA antibodies is associated with lymphopenia, photosensitive dermatitis, pulmonary disease, and renal disease in lupus patients (8) (9) (10) (11) (12) (13) , suggesting a pathogenic role for these antibodies in this disease.
Recent studies have shown heterogeneity in the molecular structure of the Ro/SSA antigen. Anti-Ro/SSA antibodies from SLE patients eluted from Western blots of human lymphocyte extracts indicate that a 60-and 52-kD protein are associated with the hY Ro/SSA RNAs in nucleated cells (14, 15) . In human red blood cells, Ro/SSA particles contain either a 60-or 54-kD polypeptide. Immunoprecipitation of these particles reveals that they associate with only a subset of the hY RNAs (15) .
Studies from our laboratory have shown that the 60-kD Ro/SSA polypeptides in lymphocyte and red blood cell are distinct but related. Most patient autoantibodies which bind to the 60-kD Ro/SSA lymphocyte polypeptide cross-react with the 60-kD red blood cell Ro/SSA polypeptide. However, certain patients produce antibodies that recognize only one form ofthis protein. Similarly, antibodies binding to the lymphocyte 52-kD Ro/SSA polypeptide cross react in most but not all cases with the red blood cell 54-kD Ro/SSA protein. Thus, the four isoforms of Ro/SSA fall into two non-cross-reacting families (16) .
The majority of biochemical studies of Ro/SSA polypeptides have centered around the analysis of the 60-kD containing particles. Although Western blot analyses using different patient sera and tissue extracts show no evidence for heterogeneity in the 60-kD proteins, three different sequences of the gene encoding 60-kD Ro/SSA have been reported. Two of them differ only in the region encoding the carboxy-terminal amino acid residues (17, 18) ; the third is entirely different from these two sequences (19) . To determine the relationship between the 60-and 52-kD Ro/SSA proteins, we have cloned a gene which encodes the human 52-kD form of the Ro/SSA protein. In this study, we report the sequence of this gene and show that it is unique from the reported 60-kD Ro/SSA genes. The 52-kD Ro/SSA polypeptide is not a degradation product of the 60-kD form, consistent with the lack of immunological cross-reactivity between these proteins. Furthermore, the 52-kD Ro/SSA gene encodes both zinc finger and leucine zipper motifs, both ofwhich have been implicated in nucleic acid and protein interactions. This study demonstrates further the considerable heterogeneity that exists in the Ro/SSA autoantigenic particles, and has important implications in the generation of an autoimmune response to Ro/SSA in patients with certain rheumatic diseases.
Methods
Adsorption ofEscherichia coli antibodies. Sera from patients with systemic lupus erythematosus (20) and controls were adsorbed against E. coli after lysis with the bacteriophage vector A gt 1I to deplete naturally occurring anti-E. coli antibodies. Briefly, five petri dishes with 30,000-Human 52-kD RoISSA Ribonucleoprotein Complementary DNA 177 50,000 plaque-forming units (pfu) were plated with E. coli strain Y 1090 cells on LB agar and grown for 3.5 h at 420C. The cultures were overlaid with a single nitrocellulose filter for 3 h on one side and 2 h on the other side at 370C. Filters were washed in TBST (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween-20), and then sequentially incubated at room temperature with a 1:100 dilution ofhuman serum. Adsorptions were monitored by exposing a small piece of each filter with an alkaline phosphatase-conjugated, goat anti-human IgG antisera (Sigma Chemical Co., St. Louis, MO) . The sections of these filters were then reacted with nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) according to the ProtoBlot system (Promega Biotec, Madison, WI).
Screening a human cDNA library. A human thymocyte cDNA library cloned in the X gt 11 expression vector was obtained from Clontech Laboratories, Palo Alto, CA. 30,000 pfu per petri dish were plated with E. coli Y1090 cells on LB agar. The partially lysed E. coli lawn was overlaid for 3 h at 370C with a nitrocellulose membrane which had previously been soaked in 10 mM isopropyl-fl-D-thiogalactopyranoside (IPTG). Filters were washed in TBST, incubated with an E. coli-absorbed patient serum which contained antibodies to the 52-kD Ro/SSA protein, and screened using the alkaline phosphatase method described above. Blue-colored plaques were purified using the same patient serum.
Affinity purification of antibodies from patient serum. Antibodies were affinity-purified from two sources using either nitrocellulose membranes from (a) Western blots of polyacrylamide gel-separated human lymphocyte extracts, or (b) blots of IPTG-induced proteins from plaque purified bacteriophage clones. Lymphocytes were lysed by sonication in water and centrifuged to remove debris. Supernatants were reduced, heat-denatured, and subjected to electrophoresis on a 10% polyacrylamide gel. Proteins were electrophoretically transferred to nitrocellulose membranes (21) . To localize the region of the filter containing 52-kD proteins, a small section of the membrane was reacted with serum from a patient containing anti-52-kD Ro/SSA autoantibodies. Binding of patient antibodies was detected as described above. The corresponding section of the remainder of the membrane was then excised and incubated with patient serum using a modification of a method by Krohne et al. (22) . Briefly, the membrane was incubated with serum for 30 min at 37°C, and the antibodies were eluted with 3 M sodium (vs. potassium) thiocyanate. The elution process was repeated five times and the resulting solution was concentrated -50-fold using a Centriprep 30 concentrator (Amicon Division, W. R. Grace, Danvers, MA). Antibodies which bound to 60-kD Ro/SSA proteins, or proteins produced in IPTG-induced bacteriophage plaques were eluted in an identical manner.
Immunoprecipitation of RoISSA proteins and h Y RNAs. Affinitypurified antibodies isolated from IPTG-induced bacteriophage plaques were used to immunoprecipitate nucleic acids bound to Ro/SSA proteins from HeLa cells (23). These antibodies were bound to staphylococcal protein A-coated Sepharose CL-4B beads (Pharmacia, Inc., Piscataway, NJ). HeLa cells were lysed by sonication in the presence of 0.05% NP-40 and mixed with these beads. Bound material was eluted with 0.3 M sodium acetate and 1% SDS, and subjected to phenol/chloroform extraction. Ethanol precipitated nucleic acids were dissolved in electrophoresis sample buffer and subjected to PAGE in the presence of 7 M urea. Silver staining was used to detect nucleic acids.
Characterization and sequencing ofcDNA in bacteriophage clones. DNA was extracted from bacteriophage after pronase digestion. Restriction enzyme digestions were carried out under conditions recommended by the enzyme's suppliers. DNA was subjected to electrophoresis in 0.8% agarose gels and transferred to nylon membranes (Amersham Corp., Arlington Heights, IL) by the method of Southern (24) . Isolated inserts were radioactively labeled with [a-32P]dCTP using random hexamer primers (25, 26) , and hybridized to nylon membranes in cross-hybridization studies. Following hybridization, membranes were washed under high stringency conditions to 0.1 X SSPE (15 mM NaCl, 1 mM NaH2PO4, 0.1 mM EDTA, pH 7.0) and 0.1% SDS at 65°C. Hybridization was detected by autoradiography.
The cDNA inserts from bacteriophage clones were purified after electrophoresis in 5% NAV-bis-acrylylcystamine cross-linked polyacrylamide gels (Bio-Rad Laboratories, Richmond, CA), reduction with 2-mercaptoethanol, and DEAE ion-exchange chromatography. The resulting fragments were subcloned into an EcoRI-digested Ml 3mp19 bacteriophage vector (27, 28) . Additional DNA from clone FH 18.1 was digested with restriction enzymes chosen for their ability to produce DNA fragments which could be directly subcloned into the multiple cloning sites of M I 3mp 19. After ligation of these inserts to the vectors with T4 DNA ligase (Bethesda Research Laboratories, Gaithersburg, MD), DNA was transformed in E. coli strain JM103. Single stranded DNA from M 13 subclones was prepared (27) and subjected to nucleotide sequencing using the dideoxy chain-termination method (29) with T7 DNA polymerase (30) (U.S. Biochemical Corp., Cleveland, OH). Nucleotide sequences were also determined from deletion subclones produced with T4 DNA polymerase (31) .
Computer analyses of nucleotide and amino acid sequences were performed using the Sequence Analysis Software Package ofthe Genetics Computer Group, University of Wisconsin (32) 
Results
Isolation ofthe 52 kD Ro/SSA cDNA-clones. A human thymocyte cDNA library cloned into the bacteriophage vector X gt 1I was screened with the lupus patient serum DU after IPTG induction of the f3-galactosidase gene (Fig. 1 A) DU antibodies to these bacteriophage clones was IPTG dependent, indicating that this reactivity was specific for cDNAencoded epitopes, and not due to bacterial or vector-encoded antigens. IPTG-induced proteins expressed in these clones were screened with a panel of sera from different SLE patients, with affinity-purified antibodies, as well as with normal human sera. All sera were adsorbed to remove naturally occurring anti-E. coli antibodies before use. The autoimmune specificity of five sera tested in this study as detected in Western blots of human lymphocyte extracts is shown in Fig. 1 A. The reactivity of IPTG-induced proteins in clone Fl 18.1 with these human sera is shown in the top portion of Fig. 1 B. Lane 2 shows the reactivity detected with serum DU, the serum used in the library screening. Reactivity was also detected with a patient serum (MO) which contains only anti-52-kD Ro/SSA reactivity (lane 3). No reactivity was detected with sera from healthy controls (lane 1), or with IPTG-induced X gtl 1 infected E. coli plaques with any of these sera (bottom panels, Fig. 1 It is possible that antibodies in the sera used above were binding to epitopes in these clones not detected in Western blots. In order to test this possibility, antibodies from either BO or DA were eluted (22) from the 45-, 52-, and 60-kD regions of Western blots of human lymphocyte extracts. Antibodies which were affinity purified from the 52-kD region of human lymphocyte extracts bound to the IPTG-induced proteins in this clone ( Fig. 1 B, lane 4) . However, affinity purified anti-60-kD antibodies failed to bind to either clone (lane 5), strongly suggesting that the cDNA encoded epitopes are present on 52-but not 60-kD Ro/SSA polypeptides. Antibodies eluted from the 45-kD La/SSB area ofthe Western blot also failed to bind to proteins expressed in these clones (data not shown).
IPTG-induced proteins of clones F118. 1, F119.3, and wildtype X gtl 1 were blotted to nitrocellulose filters. These filters were exposed to E. coli-adsorbed DU serum, and bound antibodies were eluted with 3 M NaSCN. Fig. 2 shows the results of Western immunoblotting of human lymphocyte extracts with these affinity-purified antibodies. DU serum antibodies bind to the 52-kD form of Ro/SSA (lane 1). Affinity-purified antibodies from this patient which were eluted from IPTG-induced clones H Ifthis cDNA encodes the 52-kD Ro/SSA protein, a lysate of this clone should specifically block the anti-52-but not the anti-60-kD Ro/SSA reactivity detected on Western blots of human lymphocyte extracts. E. coli infected with either clone FI 18.1 or X gt 1I wild-type bacteriophage were grown in 1 liter of culture with IPTG to maximal optical density. The cells were washed, resuspended in 10 ml of water, and lysed with lysozyme and sonication. These lysates were treated with 12.5 U of DNAase I to reduce viscosity and subsequently used as blocking agents in Western blots of human lymphocytes treated with sera containing both anti-52-and anti-60-kD Ro/ SSA antibodies. Blocking of the anti-52-but not anti-60-kD Ro/SSA antibodies was observed only with lysates from the recombinant clone indicating a lack ofcross-reactivity between the recombinant protein and the 60-kD form of Ro/SSA.
To determine if the 52-kD protein detected in the previous experiment is present in a Ro/SSA ribonucleoprotein particle, affinity-purified antibodies from clones FI 18.1 and Fl 19.3 were used to immunoprecipitate particles from HeLa cells. After phenol extraction to remove proteins from the immunoprecipitated material, denaturing PAGE was performed to characterize nucleic acids that might be present in the samples. Fig.  3 shows that all hY Ro/SSA RNAs were found only when particles were immunoprecipitated with affinity-purified antibodies from clones FH18.1 and FH19.3. Small RNAs associated with La/SSB were not precipitated by these affinity purified antibodies, and no hY RNAs were observed using antibodies which were affinity-purified from wild-type A gtl 1 transfected E. coli cells or serum from a healthy control. These results suggest that the 52-kD proteins detected on Western blots are proteins present in Ro/SSA particles and that the cDNA inserts of clone F 18.1 and F119.3 encode at least a portion of this protein.
Characterization ofthe bacterially expressed Ro/SSA proteins. IPTG-induced proteins in clones F 18.1 and FH 19.3 were further examined. Lysogens were constructed for each clone in E. coli strain Y1089. After IPTG induction, crude bacterial lysates were resolved in 7.5% SDS-polyacrylamide gels, transferred to nitrocellulose filters, and developed with either a mouse anti-(%-galactosidase monoclonal antibody, DU patient serum, affinity-purified anti-52-kD Ro/SSA antibodies, or normal human sera. If the cDNA in clones FH18.1 or FI19.3 encoded a full-length polypeptide, a 168-kD fl-galactosidase fusion protein was predicted when screened with either DU serum or the mouse anti-f6-galactosidase antibody. Fig. 4 shows that bands close in size to the native f,-galactosidase, and its degradation products, were detected with mouse anti-,B-galactosidase antibodies. When using DU serum, a 48-50-kD band was unique to clones F118.1 and H19.3. A faint band -160 kD specific to these clones was detected only with patient antibodies. The lack of reactivity of a similarly sized faint band detected with anti-f-galactosidase antibodies makes it questionable as to whether this weak band is a blotting artifact or an example of a ,B-galactosidase fusion protein which is produced and rapidly cleaved in these cells to yield two polypeptides, one approximately the size of ,B-galactosidase and the other just slightly smaller than the expected size of the 52-kD Ro/SSA protein. Anti-52-kD Ro/SSA affinity-purified antibodies eluted from Western blots of lymphocyte extracts bound to the this 50-kD protein expressed in these bacteria. Furthermore, antibodies eluted from the 50-kD protein expressed in bacteria bound specifically to a 52-kD lymphocyte protein and immunoprecipitated the Ro/SSA hY RNAs (not shown). All of these findings are consistent with the cDNA insert in each clone encoding the 52-kD Ro/SSA protein.
Sequence Inserts from both clones were isolated and subcloned into the plasmid pUCl9 (28). Similarity in the nucleotide sequence of these cDNAs was demonstrated in the following ways. First, DNA from each plasmid subclone was digested with EcoRI, subjected to electrophoresis in a 0.8% agarose gel, and transferred to a nylon membrane using the method of Southern (24) . The isolated 1.8-kb insert from clone FH 18.1 was radiolabeled (25, 26) and hybridized to this Southern blot. Fig. 5 shows cross hybridization between this probe and the insert from each clone. Secondly, products of restriction enzyme digestions ofeach insert with seven restriction enzymes were subjected to electrophoresis in polyacrylamide gels. Ethidium bromide staining of these fragments revealed no apparent differences between these clones (data not shown). have been observed in DNA and RNA binding proteins (36) (37) (38) (39) , and heterogeneity in the motif structure has been reported (40) . A leucine zipper structure is also present in the 52-kD Ro/SSA protein between amino acids 211 and 232. The heptad repeat of leucine residues occurs three times in this 22-amino acid region. 12 of the 18 amino acids between these leucine residues are either uncharged polar residues, or charged amino acids, characteristic of other leucine zippers (41) . Another leucine residue is present 14 amino acids in the NH2-terminal direction from Leu-2 11, although glutamic acid rather than leucine occurs at position 204. Again, a disproportionately high number of charged and glutamine residues occur in this region, suggesting that residues 197-210 may also represent a portion of this protein's leucine zipper. Leucine zippers are proposed to exist in a-helical conformations which allow pairing between DNA-binding proteins (41, 42) . Predictions of hydrophobicity by the method of Kyte and Doolittle (43) and secondary structure by the method of Chou and Fasman (44) suggest a highly hydrophobic a-helical region in the first 24 amino acids, an extended a-helical hydrophilic region between amino acids 130 and 225, and a hydrophobic carboxy-terminal 75 amino acids. Consistent with this prediction, the leucine zipper motif of the 52-kD Ro/SSA protein occurs in a predicted a-helical region. A potential N-linked glycosylation site is located at amino acid 422. Although we are not aware ofany data on whether Ro/SSA proteins are glycosylated, the absence of this posttranslational modification in E. coli suggests that glycosylation is not required for antigenic recognition by serum autoantibodies in the panel of lupus patients studied here.
A search through the Genbank (release 60.0) and EMBL (release 19.0) nucleic acid sequence data banks revealed only two sequences with moderate similarity to the 52-kD cDNA sequence. The first 428 nucleotides in the coding region of the 52-kD Ro/SSA gene are 62% identical to the 5' portion of the mouse rpt-1 gene, whose product is involved in the downregulation of the IL-2 receptor (45). 54% of the nucleotides of this portion ofthe human rfp gene (46) . (Two gaps were inserted in each comparison to optimize the alignment of these sequences.) Furthermore, the last 411 bases of the 52-kD Ro/ SSA coding region are 64% identical with the 3' portion of the coding region of the human rfp gene (after the introduction of three gaps to optimize sequence alignments). Little similarity was found in the middle portion of the coding regions of the latter two genes.
Searches for similarities between the predicted amino acid sequence of the 52-kD Ro/SSA protein and other protein sequences in the NBRF database (release 21.0) using the algorithm of Wilbur and Gipman (47) showed a significant match only with the predicted sequence of the human rfp transforming protein. The regions ofsimilarity correspond to those identified above in the DNA. Alignment ofthese sequences reveals 42% identity in the NH2-terminal portions of these proteins, and 51% identity in their COOH-terminal regions. Using the method of Gribskov and Burgess (48), the NH2-terminal residues of these proteins are 84% similar, while the COOH-terminal amino acids are 86% similar. A comparison of the predicted amino acid sequences ofthe Ro/SSA 52-kD protein and the mouse rpt-I protein using the method ofSmith and Waterman (49) also revealed 47% identity (84% similarity) between the amino acids encoded by the 5' portions of the coding regions described above.
The NH2-terminal portions of these three proteins contain zinc finger motifs in approximately their first 145 amino acid residues. Conservation of both amino acid sequence and spacing of these motifs was found (Fig. 7) . His-100 of the 52-kD Ro/SSA sequence is absent in the other two proteins, suggesting that these residues may not form a zinc finger element. Because of the similarity between these zinc finger motifs, an additional search was made for similarities between the zinc finger region ofthe 52-kD Ro/SSA polypeptide and nine other proteins with zinc finger motifs. Ofsix comparisons with mammalian zinc finger containing proteins, similarity of the 3' end (17, 18) . A third 60-kD Ro/SSA sequence shows no similarity to either ofthese sequences or to the 52-kD sequence reported here (19) . Neither RNP-1 nor RNP-2 consensus binding sequences occur in the 52-kD Ro/SSA protein (50) (19) . The 52-kD Ro/SSA protein reported here has a predicted amino-terminal hydrophobic region of -24 amino acids (43) . Ifthese residues are removed in the formation of a mature 52-kD Ro/SSA polypeptide, a 452-amino acid protein of 51,513 D is predicted. Amino acid sequencing of purified 52-and 54-kD Ro/SSA polypeptides, or the eventual cloning ofa gene which encodes the 54-kD protein will be necessary to define the structural relationship between these two polypeptides and their posttranslational processing.
Since many of the lupus patients who produce anti-Ro/ SSA antibodies also make anti-La/SSB antibodies, the possibility that the cDNA described here encodes the La/SSB protein was also considered. We have ruled out this possibility in four ways. An absolute positive correlation was found between the presence ofanti-52-kD Ro/SSA antibodies as detected by Western blot analyses and the ability ofthose patients' antibodies to react with IPTG-induced proteins of the recombinant clones. No association between the presence of anti-La/SSB antibodies and the specificity for this clone's proteins was observed. Second, anti-La/SSB antibodies affinity purified from the 45 kD region of a Western blot failed to bind to these clones. Third, affinity purified antibodies from these clones precipitated the Ro/SSA hY RNAs, but not any of the small RNAs associated with La/SSB, and finally, the nucleotide sequence of this clone is unrelated to that of La/SSB.
The zinc finger motifs found in the 52-kD Ro/SSA protein are characteristic of proteins which bind nucleic acids (36) (37) (38) (39) (53) . Cloning of the gene from human cells indicated a portion of this gene undergoes translocation, and that this gene is expressed at high levels in mouse testis, embryos, and a variety of human and rodent tumor cell lines (46, 54) . The function of the rfp gene product has not been identified. The rpt-I protein has down-regulatory activity on the receptors for interleukin 2 in mice (45). While soluble IL-2 receptor levels have been reported to be abnormal in SLE patients (55) (56) (57) containing Ro/SSA particles have each been shown to precipi-tate La/SSB proteins (61, 62) . In addition, a monoclonal antiLa/SSB antibody has been reported which binds to Ro/SSA particles (63) . It has not been determined if the dual heptad repeat of leucine residues in La/SSB is responsible for these protein's interaction (64) . While both Ro/SSA and La/SSB particles have also been found in 45S endoribonuclease VII-RNP complexes, the sites for interactions between subunits in these complexes remain undefined (65) .
It is now clear that the 52-kD form of Ro/SSA is not a differential transcriptional or posttranslational product of the 60-kD Ro/SSA molecule. These proteins are encoded by distinct gene sequences. The fact that no cross-reaction has been observed with affinity-purified antibodies that recognize these proteins is consistent with this finding ( 16) . Three reports now exist for genes which apparently encode the 60-kD form of the Ro/SSA protein. Differences between the two most similar 60-kD Ro/SSA sequences may represent tissue specific isoforms, differential exon splicing, unusual allelic variants, or cloning artifacts ( 17, 18) . The relationship between these and the third 60-kD Ro/SSA gene is not clear (19) . However, the common characteristic of all these Ro/SSA proteins is their ability to physically associate with the small hY RNAs. Surprisingly, no similarity in the DNA or amino acid sequences was found between any of these 60-kD Ro/SSA clones and the 52-kD Ro/ SSA clone reported here. The deduced amino acid sequence of the 52-kD protein lacks similarity to other RNA binding proteins. While the RNP-binding consensus sequences defined by Dreyfus et al. (50) are not present in the 52-kD Ro/SSA antigen, they are also missing in one of the 60-kD Ro/SSA sequence, the D protein of the Sm autoantigen, and in certain viral RNA binding proteins (19, 66, 67) . The heterogeneity of these sequences (50) may indicate either that other sequences serving the same function exist but are currently unrecognized, or that the hY RNA binding of Ro/SSA proteins is dependent on a particular tertiary configuration.
While the function of Ro/SSA is unknown, it is clear that considerable heterogeneity exists in these ribonucleoprotein complexes. At least two isoforms are present in nucleated and red blood cells, and tissue specific differences in Ro/SSA proteins have recently been identified (Itoh et al., manuscript submitted for publication). While the common feature of these proteins is their ability to bind hY RNAs, the number and form ofthese RNA molecules also varies between cells (15). Accordingly, functional differences in these complexes would not be unexpected. The physical heterogeneity of these Ro/SSA particles may, in part, explain the heterogeneity in the immune response to these complexes in patients with SLE and Sjogren's syndrome. Autoantibodies to Ro/SSA are associated with particular HLA serotypes and gene markers in these patients (I 1, 68-71). We have recently reported T cell receptor restriction fragment length proteins which are associated with the presence of anti-Ro/SSA antibodies (72) . Since the antigenic portion of these complexes resides in the polypeptide, differences in the presence of particular anti-Ro/SSA antibodies between patients may be based on the ability of that patient's immune system to process and recognize epitopes which are unique to each form of the Ro/SSA polypeptides. Given the complexity of this antigenic system, a reevaluation of polymorphisms of the immune response genes ofpatients with anti-Ro/SSA antibodies is in order. The ability to purify different recombinant Ro/SSA proteins and use them in immunogenetic analyses may clarify the role of such genes in the generation of an immune response to Ro/SSA ribonucleoprotein complexes in patients with SLE and Sjogren's syndrome.
